Membrane protein-chimeric liposome-mediated delivery of triptolide for targeted hepatocellular carcinoma therapy.


Journal

Drug delivery
ISSN: 1521-0464
Titre abrégé: Drug Deliv
Pays: England
ID NLM: 9417471

Informations de publication

Date de publication:
Dec 2021
Historique:
entrez: 27 9 2021
pubmed: 28 9 2021
medline: 15 1 2022
Statut: ppublish

Résumé

Triptolide (TPL) is a diterpenoid triepoxide with broad antitumor efficacy, while lack of mechanism of action, severe systemic toxicity, and poor water solubility of TPL limited its usage. To unveil the mechanism of action and improve the pharmaceutical properties of TPL, here we explored the molecular mechanism of TPL and then fabricated TPL-loaded membrane protein-chimeric liposomes (TPL@MP-LP) and tested its anticancer efficacy against hepatocellular carcinoma (HCC). CCK8 assay, colony formation assay, EdU assay, and flow cytometry were used to examine the activity of TPL. RNA sequence and gain-and-loss of function assays were used to explore the molecular mechanisms. TPL@MP-LP was characterized by size, zeta potential, polydispersity index, and transmission electron microscopy. Cellular uptake and cell viability assay were performed to evaluate the internalization and anticancer efficacy of TPL@MP-LP

Identifiants

pubmed: 34569906
doi: 10.1080/10717544.2021.1983072
pmc: PMC8477919
doi:

Substances chimiques

Diterpenes 0
Drug Carriers 0
Epoxy Compounds 0
Liposomes 0
Membrane Proteins 0
Phenanthrenes 0
triptolide 19ALD1S53J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2033-2043

Références

Trends Pharmacol Sci. 2019 May;40(5):327-341
pubmed: 30975442
Biomed Pharmacother. 2018 Aug;104:771-780
pubmed: 29807227
Int J Nanomedicine. 2020 Nov 24;15:9355-9371
pubmed: 33262592
PLoS One. 2007 Oct 10;2(10):e1032
pubmed: 17925880
Environ Toxicol. 2016 Dec;31(12):1974-1984
pubmed: 26420756
J Am Chem Soc. 1972 Oct 4;94(20):7194-5
pubmed: 5072337
J Control Release. 2015 Dec 28;220(Pt B):727-37
pubmed: 26390807
Cancer Res. 2007 Oct 1;67(19):9407-16
pubmed: 17909050
Biochim Biophys Acta Rev Cancer. 2020 Jan;1873(1):188314
pubmed: 31682895
Trends Cell Biol. 2018 Mar;28(3):213-223
pubmed: 29241686
Eur J Med Chem. 2019 Aug 15;176:378-392
pubmed: 31121546
Food Chem Toxicol. 2013 Jul;57:371-9
pubmed: 23583804
Semin Cancer Biol. 2021 Feb;69:91-99
pubmed: 31421265
Mol Cancer Ther. 2013 Jul;12(7):1266-75
pubmed: 23635652
Nanomedicine (Lond). 2017 Aug;12(16):2007-2019
pubmed: 28745122
J Biol Chem. 2004 Aug 27;279(35):36171-4
pubmed: 15226292
Adv Healthc Mater. 2021 Jun 23;:e2100794
pubmed: 34160137
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Theranostics. 2021 Jan 1;11(5):2034-2047
pubmed: 33500707
Acta Pharmacol Sin. 2015 May;36(5):606-13
pubmed: 25864647
J Extracell Vesicles. 2015 Dec 31;4:30087
pubmed: 26725829
Mol Cancer. 2015 Feb 21;14:48
pubmed: 25743109
Pharmacol Res. 2021 Mar;165:105377
pubmed: 33484817
J Ethnopharmacol. 2014 Aug 8;155(1):67-79
pubmed: 24933225
Nat Biomed Eng. 2017 Aug;1(8):634-636
pubmed: 31015606
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
FEBS J. 2016 May;283(10):1812-22
pubmed: 26663363
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Cell Death Differ. 2010 Jan;17(1):25-34
pubmed: 19373246
Proc Natl Acad Sci U S A. 2020 May 5;117(18):9964-9972
pubmed: 32312817
Am J Surg. 2013 Apr;205(4):387-96
pubmed: 23428154
Nanomedicine (Lond). 2019 Feb;14(4):493-509
pubmed: 30694095
Curr Stem Cell Res Ther. 2020;15(1):18-23
pubmed: 30834841
J Clin Transl Hepatol. 2018 Mar 28;6(1):69-78
pubmed: 29607307
Chem Sci. 2018 Nov 27;10(5):1555-1561
pubmed: 30809374
ACS Appl Mater Interfaces. 2021 Sep 15;13(36):42411-42428
pubmed: 34464081
Small. 2021 Feb;17(6):e2005236
pubmed: 33448111
J Control Release. 2020 Feb;318:256-263
pubmed: 31846618
Expert Opin Drug Deliv. 2011 May;8(5):565-80
pubmed: 21492058
Adv Healthc Mater. 2020 Sep;9(18):e2000731
pubmed: 32864899
Acta Biomater. 2020 Jan 1;101:519-530
pubmed: 31629893

Auteurs

Yanwen Zheng (Y)

Department of Liver Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.

Fanhua Kong (F)

Institute of Hepatobiliary Diseases of Wuhan University, Transplant Centre of Wuhan University, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.

Songyang Liu (S)

College of Biology, State Key Laboratory of Chemo/Biosensing and Chemometrics, Key Laboratory for Bio-Nanotechnology and Molecular Engineering of Hunan Province, Hunan University, Changsha, China.

Xi Liu (X)

Department of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.

Dongni Pei (D)

Department of Liver Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.

Xiongying Miao (X)

Department of Liver Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH